GANX
Gain Therapeutics Inc

1,791
Loading...
Loading...
News
all
press releases
Gain Therapeutics' GT-02287 study to deliver positive findings, says Roth MKM
Gain Therapeutics' GT-02287 study to deliver positive findings, says Roth MKM...
Yahoo! Finance: News·9mo ago
News Placeholder
More News
News Placeholder
Optimistic Outlook for Gain Therapeutics Amid Progress of GT-02287 and Successful Financing
Maxim Group analyst Jason McCarthy has maintained their bullish stance on GANX stock, giving a Buy rating today. Jason McCarthy's rating is based o...
TipRanks Financial Blog·1y ago
News Placeholder
Gain Therapeutics Advances Parkinson's Treatment in Phase 1
The latest update is out from Gain Therapeutics (GANX). Gain Therapeutics, Inc. has successfully completed the multiple ascending dose phase of its...
TipRanks Financial Blog·1y ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Director Jeffrey Scott Riley Acquires 30,000 Shares
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) Director Jeffrey Scott Riley bought 30,000 shares of the business's stock in a transaction on Thursday, March 28th. The shares were acquired at...
Ticker Report·1y ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 156,700 shares, an...
Ticker Report·1y ago
News Placeholder
Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)
Related Stocks: GANX...
GuruFocus·1y ago
News Placeholder
Gain Therapeutics appoints Jonas Hannestad as CMO
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
BETHESDA, Md., April 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ( Gain , or the Company ), a clinical-stage biotechnology company leading the discovery and development of...
Globe Newswire·1y ago
News Placeholder
Buy Rating Affirmed for Gain Therapeutics on Promising Parkinson's Treatment and Solid Financial Outlook
Gain Therapeutics (GANX Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...
TipRanks Financial Blog·1y ago
News Placeholder
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ( Gain , or the Company ), a clinical-stage biotechnology company leading the discovery and development of...
Globe Newswire·1y ago

Latest GANX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.